GlassScriptPhysician profile
David J Davidson
NPI 1063679116
$265,182.78
in general payments reported to CMS, 2019-2025
32 companies · $41K in 2025
The $41K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $17K · 2021: $32K · 2022: $66K · 2023: $55K · 2024: $23K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Consulting Fee: $16K · Food and Beverage: $5,003 · Travel and Lodging: $224 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,238.19 |
| Consulting Fee | $15,785.00 |
| Food and Beverage | $5,002.98 |
| Travel and Lodging | $223.58 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124,334.80 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $53,745.08 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $28,430.67 | 2020-2025 | Nexletol |
| Amryt Pharma Holdings LTD | $16,718.06 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $13,318.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $8,895.58 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $8,658.77 | 2025 | Tryngolza |
| Heartflow, INC. | $6,750.00 | 2023-2025 | Ffrct |
| Akcea Therapeutics, INC. | $1,820.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.75 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $292.66 | 2021-2025 | Wainua, Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $203.79 | 2022-2025 | |
| Boston Scientific Corporation | $176.98 | 2022-2025 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $160.37 | 2023-2025 | Verquvo |
| Medtronic, INC. | $148.05 | 2021-2025 | Linq II, Corevalve Evolut R |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $145.52 | 2022-2024 | Camzyos |
| Abiomed | $141.71 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $119.46 | 2023-2025 | Xarelto, Opsumit, Opsynvi |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $113.68 | 2025 | |
| Abbott Laboratories | $106.99 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $94.72 | 2024 | |
| Bridgebio Pharma, INC. | $94.69 | 2025 | Attruby |
| Lilly USA, LLC | $49.91 | 2024 | Zepbound, Jardiance |
| Lexicon Pharmaceuticals, INC. | $39.56 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $37.94 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $30.85 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $24.80 | 2023 | Definity |
| Bayer Healthcare Pharmaceuticals INC. | $23.67 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.51 | 2024 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $16.65 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.